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BACKGROUND:Parvin-b (ParvB), a potential tumour suppressor gene, is a focal adhesion protein. We evaluated the role of ParvB in the
upper urinary tract urothelial cell carcinoma (UUT-UC).
METHODS: ParvB mRNA and proteins levels in UUT-UC tissue were investigated by quantitative real-time polymerase chain reaction
and western blot analysis, respectively. In addition, the expression of ParvB in tissues from patients with UUT-UC at different stages
was evaluated by immunohistochemistry. Furthermore, biological functions of ParvB in urothelial cancer cells were investigated using
a doxycycline-inducible overexpression system and siRNA.
RESULTS: Western blot and mRNA analysis showed downregulation of ParvB expression in frozen UUT-UC tissue. Immuno-
histochemistry revealed high staining intensity of ParvB in normal urothelium, which decreased markedly at advanced stages of
UUT-UC (P¼0.0000). Moreover, ParvB was an independent prognostic indicator for disease-specific survival of patients with
UUT-UC. Functional assays indicated that overexpression of ParvB in an urothelial cancer cell line resulted in decreased cell growth
rate and ability to migrate. In contrast, knockdown of ParvB expression increased cell migration ability.
CONCLUSIONS: Downregulation of ParvB expression significantly increased urothelial cancer cell growth and migration. Down-
expression of ParvB level in UUT-UC correlated with tumour stage, and was an independent unfavourable prognostic factor for
disease-specific survival of patients with UUT-UC.
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Urothelium cell carcinoma of the upper urinary tract (UUT-UC),
which includes the renal pelvis, calyx and ureter, is relatively
uncommon and accounts for B5% of all urothelial tumours and
B10% of all renal tumours (Krogh et al, 1991; Guinan et al, 1992).
However, the incidence of patients with UUT-UC who initially
present with local advancement and metastatic tumour is
approximately B45% (Charbit et al, 1991; Racioppi et al, 1997;
Kang et al, 2003). Tumour stage and grade have been documented
as major prognostic factors in patients with UUT-UC (Cozad et al,
1995; Hall et al, 1998; Kirkali and Tuzel, 2003; Li et al, 2008).
Furthermore, even after undergoing radical surgery followed by
adjuvant therapy, UUT-UC patients with a high pT stage show
poor clinical outcomes owing to high local tumour recurrence and
distant metastases (Lerner et al, 1996; Maulard-Durdux et al, 1996;
Bamias et al, 2004; Czito et al, 2004; Kwak et al, 2006). On the
basis of the above clinical findings, studies seeking to understand
UUT-UC at the cellular level are necessary for the development of
novel therapeutic approaches and improved treatment strategies.
Cell–extracellular matrix (ECM) adhesion is crucial in various
biological processes, including cell migration, proliferation, gene
expression and cell survival (Hynes, 2002; Guo and Giancotti, 2004;
Lee and Juliano, 2004). Proteins that facilitate cell–ECM adhesion
include integrin-linked kinase (ILK), talin, PINCH, paxillin,
a-parvin (ParvA), b-parvin (ParvB) and focal adhesion kinase.
These proteins are critically involved in the regulation of cell
survival and morphology (Tu et al, 1999, 2001; Nikolopoulos and
Turner, 2001; Olski et al, 2001; Wu and Dedhar, 2001; Yamaji et al,
2001). Evidence suggests that a PINCH–ILK–parvins complex is
a key component that mediates cell–ECM adhesion (Legate
et al, 2006). Proteins belonging to the parvin family, including
ParA, ParB and g-parvin (ParvG), in mammals are coded by three
different genes. These parvins possess identical domain architec-
ture and share a high level of sequence similarity (Korenbaum
et al, 2001; Sepulveda and Wu, 2006). Although ParvA and ParvB
are widely expressed and show overlapping expression in various
tissues, ParvG expression is restricted to the haematopoietic
system (Korenbaum et al, 2001). Parvin-b maps to chromosome
22q13.31 (Korenbaum et al, 2001). Castells et al (2000) showed
that a deletion on chromosome 22q13 is involved in breast
and colorectal cancer and suggested the existence of tumour
suppressor genes within this region (Castells et al, 2000).
Revised 11 June 2010; accepted 8 July 2010; published online 24 August
2010
*Correspondence: Dr S-T Pang; E-mail: jacobpang@cgmh.org.tw
British Journal of Cancer (2010) 103, 852–860
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMoreover, Mongroo et al (2004) showed that ParvB inhibits
ILK-mediated signalling and that ParvB is downregulated in
advanced breast cancer. In our previous studies, we also found that
ParvB is downregulated in transitional cell carcinoma by utilising a
cDNA microarray technique (unpublished data). Here, we further
characterise the biological roles of ParvB in UC and evaluate its
potential biomarker role in UUT-UC.
MATERIALS AND METHODS
Patients and tumour specimens
From January 1998 to December 2008, patients with UUT-UC
treated at Lin-Kou and Chia-Yi Chang Gung Memorial Hospital
were reviewed retrospectively. Immunohistochemical staining were
performed using 129 paraffin-embedded UUT-UC specimens
retrieved from the Department of Pathology; disease-free survival
analyses were conducted on the basis of clinical chart reviews.
Nineteen pairs of normal and urothelial tumour specimens obtained
from the Chung Gung Memorial Hospital Tissue Bank were used
for quantitative real-time polymerase chain reaction (PCR). Seven
patients had non-muscle invasive tumours (Ta, T1) and 12 had
muscle invasive tumours (T2, T3 and T4). Tumour grade was
evaluated using 1998 World Health Organization grading system
(Epstein et al, 1998), whereas tumour stage was determined using
2002 AJCC TNM classifications (Greene et al,2 0 0 2 ) .
RNA extraction and quantitative RT–PCR
Total RNA extraction from tumour tissue, normal urothelium and
cell lines was performed using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Total RNA
was quantified and qualified by spectrophotometry (NanoDrop
Technology Inc., Wilmington, DE, USA). RNA samples treated
with RQ1 RNase-Free DNase I (Promega, Madison, WI, USA) were
reverse transcribed with SuperScript (Invitrogen) using oligo-dT
primers. Quantitative real-time PCR (Q-PCR) reactions were
performed in a total volume of 20ml using SYBR GreenSuperMix
(BioRad, Hercules, CA, USA) and a BioRad iCycler iQ Real-Time
Detection System according to the manufacturer’s instructions.
Primers with the following sequences were used: ParvB – forward,
50-AATGTGGCTGAGGTGACACA-30 and reverse, 50-TCTTCCCGTGA
ATTGAGTCC-30;G A P D H–f o r w a r d ,5 0-GAAGGTGAAGGTCGGAGT
C-30 and reverse, 50-GAAGATGGTGATGGGATTTC-30. Quantitative
r e a l - t i m eP C Rc y c l ec o n d i t i o n sw e r e3m i na t9 5 1C, 15s at 951Ca n d
45s at 601C for 45 cycles. Polymerase chain reaction reactions were
performed in triplicate and relative expression levels of ParvB in
normal and tumour tissues were calculated by normalising to GAPDH
expression levels by using the comparative CT method. CT represents
the cycle numbers at which the amplification reaches a threshold level
that is chosen to lie within the exponential phase of all PCR reactions.
Data were analysed using the iCycle iQ system software (BioRad).
Western blot analysis
Frozen tumour, normal urothelium tissue and cell lines were
lysed in the PRO-PREPTM Protein Extraction Solution (iNtRON
Biotechnology, Seoul, Korea) according to the manufacturer’s
instructions. Proteins were quantified by Bradford analysis. For
western blot analysis, cell lysates were separated using 12% SDS–
PAGE and then transferred onto nitrocellulose membranes
(Millipore Corporation, Billerica, MA, USA). Membranes were
blocked with 3% BSA in TBS-T buffer (150mM NaCl, 10mM Tris
(pH 8.0) and 0.05% Tween 20) at room temperature for 1h or
overnight at 41C, and then incubated with the following primary
antibodies: ParvB (1:1000; Abnova, Newark, DE, USA), b-actin
(1:50000, MAB1501; Chemicon, Temecula, CA, USA) or GAPDH
(1:1000, MAB374; Chemicon); incubation period was 1h at room
temperature (ParvB) or overnight at 41C( b-actin and GAPDH).
Incubation with secondary antibodies (AP124P; Chemicon) was
performed for 1h at room temperature. Immunoblots were
visualised using a chemiluminescence ECL system (Millipore
Corporation), and western blot data were quantified using the
BIO-PROFIL BIO-1Dþþsoftware.
Stable knockdown of ParvB
HuSH 29-mer short-hairpin RNA (shRNA) constructs were
generated against human ParvB (OriGene Technologies, Rockville,
MD, USA). The shRNA (ATGTGGCTGAGGTGACACAGTCCGA
AATA) construct was cloned in the pRS plasmid vector under the
control of the U6 promoter. The control vector expressed shRNA
against GFP shRNA. The different constructs were transfected into
an urothelial cancer cell line (MGH-U1) at 60% confluency by
using FuGENE reagent (Roche, Indianapolis, IN, USA) according
to the manufacturer’s instructions. After 72h, the transfected cells
were cultured under puromycin (Invitrogen) selection at 3mgml
 1
concentration. After 2 weeks of selected growth, several individual
colonies were chosen and grown separately in a single well of a 12-
well dish. Further selections of stably transfected cells were
performed and grown in puromycin culture medium.
DNA constructs
To generate expression vectors encoding the TetR gene, DNA
fragments encoding the TetR gene was obtained from pcDNA6/TR
expression vector (which includes the CMV promoter and rabbit
b-globin intron II (IVS); Invitrogen) and then cloned into the PmII/
SaII sites of the pRS expression vector (OriGene Technologies),
resulting in the generation of a pRS-TetR expression vector. The
1.2-kb coding region of human ParvB gene was amplified from a
pcDNA3.1myc/ParvB plasmid (kindly donated by Dr Hannigan) by
PCR and then cloned into a pcDNA4/TO/VSVG vector to generate
the pcDNA4/TO-ParvB-VSVG vector. All constructs were verified by
nucleotide sequencing.
Stable transfection and DOX-inducible overexpression
of ParvB-VSVG
The pRS-TetR plasmid DNA was introduced into MCH-U1 cells
using FuGENE transfection reagent (1:4). At 72h post-transfec-
tion, the cells were subcultured into a 100-mm culture dish, and
then subjected to puromycin at 3mgml
 1 concentration. MGH-U1
cell lines stably transfected with pRS-TetR in 24-well dishes were
super-transfected with 0.3mg of pcDNA4/TO-ParvB-VSVG plasmid
DNA. Again, after 72h of transfection, the cells were subcultured
into a 100-mm culture dish. In addition to puromycin, Zeocin
(Invitrogen) at 300mgml
 1 concentration was added to cultures to
select cell clones that were stably transfected with both pRS-TetR
and pcDNA4/TO-ParvB-VSVG. We confirmed the presence of the
stable clone overexpressing the ParvB-VSVG gene by stimulating
the cells with 1mgml
 1 doxycycline (DOX). The stable clone with
inducible ParvB-VSVG expression was designated ParvB-V2 (clone
number 2).
Cell growth curve assay
Cell lines were seeded on 12-well plates at a density of 5 10
4 cells
per well with complete culture medium and allowed to adhere to
the plate overnight. For inducible cell lines, cells were cultured in
triplicate with or without DOX (0.1mgml
 1) for 72h at 371Ci n
a5 %C O 2 atmosphere. The total number of cells that was counted
in each plate was counted every 24h and the mean value was
calculated.
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Invasion assays were performed in the transwell chambers with
an 8-mm pore size polycarbonate filter (Corning-Costar, Corning,
NY, USA) coated with Matrigel (BD Biosciences, San Jose, CA,
USA) for 1h at 371C in a serum-free medium. Cells were seeded on
transwell inserts at a density of 5 10
4 cells per well in the serum-
free medium in the upper chamber (above the transwell insert) for
4 and 8h at 371C in a humidified 5% CO2 atmosphere. The lower
chamber (below the insert) contained 10% foetal bovine serum,
which was used as a chemoattractant. Following migration, the
cells were fixed with methanol for 10min and stained with
Giemsa for 30min. Cells were counted in three randomly chosen
microscopic fields at 10 magnifications.
Immunohistochemical staining
Immunohistochemistry (IHC) was performed, using the standard
streptavidin–biotin complex method. Serial sections from appro-
priate pairs of normal urothelium and tumour tissue were cut and
processed for IHC staining. Briefly, tissue sections (4mm thick)
were deparaffinised with xylene and rehydrated in ethanol (Sigma
Chemical Co., St Louis, MO, USA). For antigen retrieval, tissue
sections were boiled in sodium citrate buffer for 20min.
Endogenous peroxidase activity was blocked by treatment with
3% hydrogen peroxide for 15min and tissue sections were then
incubated with 3% bovine serum for 30min. Sections were
incubated with primary monoclonal anti-ParvB antibody at 1:50
dilution overnight at 41C. The sections were then further incubated
with biotinylated goat anti-mouse antibody for 30min followed by
incubation with the streptavidin–biotin horseradish peroxidase
complex for a further 60min. The peroxidase reaction was
visualised using a liquid DAB substrate kit (Dako, Carpinteria,
CA, USA). All sections were counterstained with haematoxylin for
15s. Sections incubated with phosphate-buffered saline were used
as negative controls. Renal tubule tissues were used as positive
controls. Two observers (W, CF and P, ST) blind to clinical
features and pathology analysed the intensity of IHC staining using
a consensus method. In brief, cytoplasmic IHC staining intensity
in the cancer area was scored as absent, weak, medium or strong
relative to adjacent normal renal tubule tissue or normal
urothelium. The strong, medium and weak expressions in IHC
were defined as positive staining and, in contrast, the absent
expression as negative staining.
Survival analysis and statistics
Disease-specific survival was determined using the Kaplan–Meier
method, followed by the log-rank test. A univariate analysis with
the log-rank test and Cox hazard regression was applied to assess
the value of the following prognostic factors in predicting disease-
specific survival: patient age (exceeding the mean age of the patient
population), gender (male vs female), tumour grade (1 and 2 vs 3),
tumour size (2, 2–5 or 45cm), number of tumours (one focus vs
multiple foci), tumour location (pelvis, ureter or both), ParvB
staining (positive vs negative) and vascular invasion (determined
microscopically). Statistical procedures were performed using
commercially available statistical software (SPSS, SPSS Inc.,
Chicago, IL, USA).
RESULTS
Aberrant expression of ParvB mRNA and protein in
tumours and normal urothelium
We performed quantitative RT–PCR on RNA isolated from
19 patient-matched UUT-UC and normal urothelium tissues.
Parvin-b mRNA expression was downregulated in all tumours
(Figure 1A). As ParvB mRNA expression was downregulated in
UUT-UC, we examined ParvB protein levels. Parvin-b protein
levels from 10 patient-matched normal urothelium and tumour
tissues were assessed. Downregulation of ParvB protein levels were
detected in seven of 10 tumours (Figure 1B). Furthermore, ParvB
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Figure 1 The study of ParvB mRNA (A) and protein level (B) in human upper urinary tract urothelial carcinoma in paired samples indicated that ParvB
was downregulated in tumour sample as compared with normal tissue. Error bars indicate standard deviation for triplicate experiment data (&: normal
urothelium; ’: tumour).
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Our results show that ParvB is downregulated in UC tumours at
both mRNA and protein levels.
Dysregulation of ParvB influences cell growth and
migration
The downregulation of ParvB expression in the UUT-UC tumours
prompted us to investigate whether dysregulation of ParvB
affects in cell growth and invasion. An MGH-U1-inducible cell
line expressing the ParvB-VSVG protein, designated as ParvB-V2,
was used for these experiments. We determined the minimum dose
of DOX (0.1mgml
 1) that induced ParvB-VSVG protein expression
(Figure 2A-1). The ParvB-V2 cell lines were treated with
0.1mgml
 1 of DOX for 24, 48 and 72h. The expression of ParvB-
VSVG protein was confirmed by western blotting (Figure 2A-2).
Compared with the wild-type cell line, overexpression of ParvB-
VSVG in the ParvB-V2 cell line resulted in significantly decreased
cell growth (P¼0.012) and migration (P¼0.001) (Figure 2B and C).
Thus, we proposed that downregulation of ParvB expression will
increase cell growth and invasive properties. Parvin-b-siRNA-
treated MGH-U1 cell lines were used to confirm this hypothesis.
Downregulation of ParvB protein expression in ParvB-siRNA-
treated MGH-U1 cell lines was confirmed by western blotting using
a ParvB monoclonal antibody (Figure 3A). We also checked the
ILK protein level, a ParvB interaction protein, which did not show
significant change after the knockout of ParvB (data not shown).
Compared with parental MGH-U1 cells transfected with vector
only, reduced expression of ParvB in ParvB-siRNA-treated MGH U1
cells was accompanied by significantly increased cell migration
(P¼0.000) (Figure 3B and C). These results show that dysregulation
of ParvB is associated with cell invasive properties in UC.
Immunohistochemical staining and survival analysis
To determine whether ParvB is a prognostic factor in patients
with UUT-UC, immunohistochemical analysis of paraffin-
embedded UUT-UC specimens was performed. The relation-
ships between ParvB expression and clinical demographic
characteristics of patients with UUT-UC are shown in Table 1.
Immunohistochemistry revealed ParvB expression in the cyto-
plasm of UC cells. Comparison of ParvB expression levels revealed
downregulation in UC specimens relative to normal urothelium,
with the lowest level of ParvB expression in muscle invasive
tumours relative to non-muscle invasive tumour (Figure 4).
Moreover, this study also showed a strong negative correlation
for staining intensity in relation to pT stage, tumour grade and
tumour size (Table 1). In contrast, vascular invasive property,
which significantly influences prognosis in patients with
UUT-UC, did not correlate with ParvB expression (Table 1). We
further investigated whether ParvB expression can be used as
an independent prognostic factor. According to Kaplan–Meier
analysis with the log-rank test, tumour grade, pT stage, tumour
size, vascular invasion and downexpression of ParvB level were
unfavourable factors for disease-specific survival of patients with
UUT-UC (Figure 5). The disease-specific 5-year survival rate is
76%. Furthermore, Cox hazard regression analysis showed that pT
stage, ParvB expression and vascular invasion were independent
unfavourable factors for disease-free survival of patients with
UUT-UC (Table 2).
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ParvB is a focal adhesion binding protein highly expressed in the
skeletal muscle, heart, spleen and kidney (Korenbaum et al, 2001).
Parvin-b, also known as affixin, was identified first by Yamaji et al
(2001). Parvin-b does not possess intrinsic catalytic activity and
exerts its effect through interaction with other proteins such as
ILK, a-actinin and aPIX (Sepulveda and Wu, 2006). The major
protein that interacts with ParvB is ILK. Parvin-b contains
2 calponin homology (CH) domains, CH1 and CH2, in the
C-terminal regions. Important functions have been identified
for ParvB in integrin-mediated cell adhesion, regulation of cell
morphology and cell motility, which are mediated through
interactions with ILK by the CH2 domain. Although several
ParvB isoforms have been identified, the biological functions of
some of these proteins are unknown. However, because the CH
domains show high conservation among various isoforms, they are
potentially capable of interacting with ILK. Yamaji et al (2001)
showed overexpression of the ParvB CH2 domain in CHO cell,
which is phosphorylated by ILK inhibited cell migration.
Furthermore, the interaction of ParvB with a-actinin is induced
by the phosphorylation of ParvB CH2 domain, which is dependent
on ILK kinase activity. Mishima et al (2004) found that interaction
between ILK and ParvB is necessary for integrin signalling that
results in Cdc42/Rac1 activation through aPIX. Zhang et al (2004)
have shown that ParvA and ParvB are co-expressed in human cells.
Parvin-a promotes intracellular ILK function, whereas ParvB has
an inhibitory effect. Overexpression of ParvB inhibited the
formation of the ILK–ParvA complex and promoted apoptosis
in HeLa cells (Zhang et al, 2004). Mongroo et al (2004) showed
that ParvB mRNA and protein levels are downregulated in breast
cancer cell lines and advanced breast cancer tumours. These
authors also showed that loss of ParvB expression leads to the
upregulation of ILK activity in tumour cells, whereas expression of
ParvB suppressed anchorage-dependent growth in breast cancer
cell lines. Our analysis shows that ILK protein level did not alter
after the downregulation of ParvB by siRNA. However, we would
expect that ILK activity may be increased as shown by Mongroo
in other cell line system. In addition, the same authors recently
showed that ParvB suppressed breast cancer growth in vivo by
decreasing cell proliferation (Johnstone et al, 2008). In this study,
we found that ParvB mRNA and protein levels are downregulated
in both UC cell lines and human UUT-UC cells. Moreover, we have
shown that ParvB protein levels in advanced UUT-UC tumours are
lower than those in superficial UUT-UC tumours. Similarly, IHC
analyses performed in this study also revealed lower staining
intensities for ParvB in cancer cells relative to normal urothelium
cells. The extent of ParvB downregulation correlated with disease
progression. We found that overexpression of ParvB in a DOX-
inducible ParvB-V2 cell line resulted in suppressed cell growth
and migration. In contrast, knockdown of ParvB expression in the
MGH-U1 cell line enhanced cell invasive properties. However,
lower levels of ParvB did not alter the growth rate of MCH-U1 cells.
These results suggest that the expression of ParvB is essential for
UC cell growth and migration.
Local tumour recurrence and metastasis are the major causes of
mortality in patients with UUT-UC. Our results underscore ParvB
as a regulator of cell growth and migration, which has important
implications given that cell proliferation and invasiveness are
related to tumour aggression. It remains unknown if ParvB
expression levels in various cancers are related to patient survival.
Mongroo et al (2004) first showed downregulation of ParvB
expression in advanced breast cancer, although they did not
examine if a correlation exists between ParvB expression and
patients outcomes. To our knowledge, there are no previous
reports with regard to the relationship between ParvB expression
and cancer progression. This study is the first report that evaluated
the possibility of a relationship between ParvB expression levels
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Figure 3 (A-1 and -2) ParvB was successfully knocked down using siRNA in urothelial carcinoma cell line. (B) The knockdown of ParvB did not affect
tumour cell growth rate, but (C) did significantly promote cell migration (P¼0.000) (&: WT; W: Ctrl; m: shRNA-6).
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sTable 1 Results of ParvB expression and clinicopathological characteristics in 129 patients with upper urinary tract urothelial cell carcinoma
Expression of ParvB
Positive Negative
Characteristics No. n % n % P-value Median PFS P-value for PFS
Total no. 129 78 60.5 51 39.5
Gender 0.542 0.306
Male 44 25 56.8 19 43.2 38
Female 85 53 62.4 32 37.6 57
Age (years) 0.155 0.255
o66.9 58 39 67.2 19 32.8 67
466.9 71 39 54.9 32 45.1 28
Location 0.804 0.854
Pelvis 66 39 59.1 27 40.9 61
Pelvis and ureter 26 15 57.7 11 42.3 10
Ureter 37 24 64.9 13 35.1 55
Grade 0.027 0.109
Low 76 52 68.4 24 31.6 56
High 53 26 49.1 27 50.9 36
T stage 0.000 0.000
Ta 31 28 90.3 3 9.7 61
T1 18 17 94.4 1 5.6 83.5
T2 23 9 39.1 14 60.9 48
T3 46 20 43.5 26 56.5 17.5
T4 11 3 27.3 8 72.7 3
Tumour size (cm) 0.021 0.004
o2 27 21 77.8 6 22.2 67
2–5 79 48 60.8 31 39.2 45
45 23 9 39.1 14 60.9 10
Tumour foci 0.687 0.482
1 104 62 59.6 42 40.4 54.5
^2 25 16 64 9 36 40
Vessel invasion 0.607 0.000
Positive 13 7 53.8 6 46.2 6
Negative 116 71 61.2 45 38.8 58
Abbreviations: ParvB¼parvin-b; PFS¼progression-free survival.
A B
C D
Figure 4 Examples of immunohistochemical staining intensity of ParvB in upper urinary tract urothelium cell carcinoma: (A) strong, (B) moderate,
(C) weak and (D) absent.
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ParvB expression is inversely correlated with the clinical progres-
sion of UUT-UC. This study showed that ParvB expression
levels reversely correlated with tumour grade, tumour stage and
tumour size. Furthermore, according to the univariate and Cox
hazard regression analysis, high T stage, vascular invasion and
low ParvB expression were unfavourable factors for disease-free
survival. These clinical findings were matched to molecular
results: low ParvB expression increased tumour cell growth and
invasion.
Biological functions mediated by ParvB are dependent on inter-
action with ILK. ILK which is composed of N-terminal ankyrin
repeats, a pleckstrin homology-like domain and a C-terminal
kinase catalytic domain, is implicated in the regulation of
anchorage-dependent cell growth, cell survival, cell motility, cell
invasion and migration, angiogenesis and epithelial–mesenchymal
transition (Hannigan et al, 2005). It is understood that ILK can
activate a range of biological pathways depending on cell type in
addition to being critical in development, which was shown by
lethality in ILK-null mutant mice at the embryonic stage (Sakai
et al, 2003). Recent evidence indicates that ILK expression is
increased in various tumours, including prostate cancer, colon
cancer, gastric cancer, ovarian cancer, Ewing’s sarcoma, melanoma
and breast cancer (Chung et al, 1998; Persad et al, 2000; Graff et al,
2001; Ito et al, 2003; Zellweger et al, 2005; Bravou et al, 2006;
Rosano et al, 2006; Kim et al, 2007; Wong et al, 2007; Assi et al,
2008). To our knowledge, the role of ILK in UUT-UC has not
been examined to date. This study showed the T-stage factor
corresponding to the depth of tumour invasion; low ParvB
expression corresponding to the ability of cell invasiveness and
vascular invasion are the independent prognostic factors for
disease-free survival. On the basis of our results, invasive capacity
1.0
A
DE F
BC
0.8
0.6
0.4
0.2
0.0
0 20 40 60 80 100 120 140
Months after surgery Months after surgery Months after surgery
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l 1.0
0.8
0.6
0.4
0.2
0.0
05 0 100 0 20 40 60 80 100 120 140
Months after surgery
0 2 04 06 08 0 1 0 0 1 2 0 1 4 0
Months after surgery
0 2 04 06 08 0 1 0 0 1 2 0 1 4 0
Months after surgery
0 20 40 60 80 100 120 140
0.0
0.2
0.4
0.6
0.8
1.0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l < 2 cm
2-5 cm
> 5 cm
Positive stain
Negative stain
No vascular invasion
Vascular invasion
Low grade
High grade
T0, T1
T2
T3
T4
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
i
s
c
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
Figure 5 Kaplan–Meier estimation of disease-specific survival of patient with primary upper urinary tract urothelium cell carcinoma against: (A) tumour
grade (P¼0.0121); (B) pT stage (P¼0.0000); (C) tumour size (P¼0.0002); (D) tumour vascular invasion (P¼0.0000); (E) ParvB staining intensity
(P¼0.0000); and (F) disease-specific 5-year survival curve.
Table 2 Univariate and multivariate analysis of potential prognostic
factors for disease-specific survival in patients with upper urinary tract
urothelial cell carcinoma
Univariate Multivariate
Characteristics Statistics P-value 95% CI P-value
Gender 0.79 0.3739 0.364–1.979 0.705
Age 1.68 0.1953 0.847–6.412 0.101
Location 0.10 0.7494 0.859–3.649 0.150
Grade 6.30 0.0121 0.492–3.054 0.661
pT stage 41.57 0.0000 2.381–11.688 0.000
Tumour size 13.7 0.0002 0.380–1.872 0.844
Tumour foci 0.01 0.9210 0.402–3.661 0.731
Vascular 54.52 0.0000 1.465–8.785 0.005
ParvB staining 18.31 0.0000 0.161–0.987 0.047
Abbreviations: CI¼confidence interval; ParvB¼parvin-b.
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sof tumour cells is an important factor related to prognosis in
patients with UUT-UC. Interestingly, ParvB mediates its biological
function by interacting with ILK; the signalling pathways induced
by ILK may vary according to the cell type. The exact signalling
pathways affected by knocking down ParvB expression in UUT-UC
are not yet clear. In future study, it will be interesting to further
dissect the role of ParvB-ILK and other potential signalling
pathway that involve in UUT-UC pathogenesis.
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